680 related articles for article (PubMed ID: 28492339)
21. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
Stilgenbauer S; Eichhorst B; Schetelig J; Hillmen P; Seymour JF; Coutre S; Jurczak W; Mulligan SP; Schuh A; Assouline S; Wendtner CM; Roberts AW; Davids MS; Bloehdorn J; Munir T; Böttcher S; Zhou L; Salem AH; Desai M; Chyla B; Arzt J; Kim SY; Verdugo M; Gordon G; Hallek M; Wierda WG
J Clin Oncol; 2018 Jul; 36(19):1973-1980. PubMed ID: 29715056
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
25. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
Daniel C; Mato AR
Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
[TBL] [Abstract][Full Text] [Related]
26. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract][Full Text] [Related]
27. Therapeutics targeting Bcl-2 in hematological malignancies.
Ruefli-Brasse A; Reed JC
Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
[TBL] [Abstract][Full Text] [Related]
28. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
29. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.
Fischer K; Al-Sawaf O; Hallek M
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):357-362. PubMed ID: 33275717
[TBL] [Abstract][Full Text] [Related]
30. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
Olin JL; Griffiths CL; Smith MB
J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
[TBL] [Abstract][Full Text] [Related]
32. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax Yields Strong Responses in CLL.
Cancer Discov; 2016 Feb; 6(2):113-4. PubMed ID: 26701089
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T; Verdugo M; Humerickhouse RA; Potluri J; Wierda WG; Davids MS
Blood; 2018 Apr; 131(15):1704-1711. PubMed ID: 29305552
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW
Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407
[TBL] [Abstract][Full Text] [Related]
36. Venetoclax in the treatment of chronic lymphocytic leukemia.
Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
[TBL] [Abstract][Full Text] [Related]
37. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
Gribben JG
Br J Haematol; 2020 Mar; 188(6):844-851. PubMed ID: 31858596
[TBL] [Abstract][Full Text] [Related]
38. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
39. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
Tambaro FP; Wierda WG
Lancet Haematol; 2020 Feb; 7(2):e168-e176. PubMed ID: 32004486
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax for the treatment of multiple myeloma.
Vaxman I; Sidiqi MH; Gertz M
Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]